SKLB1002

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BackgroundRecent studies suggested that cancer stem-like cells contribute to tumor vasculogenesis by differentiating into… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Aims/hypothesisDiabetes promotes cerebral neovascularisation via increased vascular endothelial growth factor (VEGF) angiogenic… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Psoriasis is a common chronic inflammatory skin disease and its underlying pathogenesis is still not fully understood… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Vascular endothelial growth factor receptor (VEGFR) or vascular endothelial growth factor (VEGF) inhibitors have shown only… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
A de novo VEGFR2-inhibited compound SKLB1002 which is independently developed in our laboratory has been described for… (More)
Is this relevant?
2011
2011
PURPOSE VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment… (More)
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Purpose: VEGF receptor 2 (VEGFR2) inhibitors, as efficient antiangiogenesis agents, have been applied in the cancer treatment… (More)
  • figure 1
  • figure 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?